Short-Range, High-Efficiency α-Particle Radioimmunotherapy Is an Innovative And Promising Therapeutic Strategy; Targeted Therapy Benefits From The Very High Cell-Killing Capacity Of Α-Particles

Rockville, Oct. 31, 2022 (GLOBE NEWSWIRE) -- Global demand for alpha emitters is expected to balloon at a CAGR of 21% and reach a market size of US$ 6.7 billion by the end of 2032, says Fact.MR, a market research and competitive intelligence provider.

A substance that emits alpha particles is known as an alpha emitter. These compounds are produced by radioactive sources. They achieve the right bio-distribution and related dose distribution to deliver effective therapy without bringing about intolerable short- or long-term side effects. When used in medical operations, alpha particles are more corrosive to tumour cells than beta particles due to their very high cell-killing rates. They don't harm the nearby healthy tissues as much. Some radionuclides utilised in treatment include radium, lead, and bismuth.

Download Sample Copy of This Report –

https://www.factmr.com/connectus/sample?flag=S&rep_id=7810

Key Takeaways from Market Study

• The global market for alpha emitters is currently valued at US$ 1 billion.

• Worldwide sales of alpha emitters are expected to reach US$ 6.7 billion by 2032.

• China’s alpha emitters market is expected to expand at a CAGR of 20% from 2022 to 2032.

• Demand for alpha emitters for ovarian cancer medical applications is predicted to rise at a CAGR of 22% from 2022 to 2032.

Rapid urbanization, ongoing healthcare infrastructure development, and rising disposable income levels, among others, are some of the key factors influencing market growth.

• The WHO report 2022 states that cancer is the biggest cause of mortality globally, accounting for approximately 10 million fatalities in 2020, or close to one in every six deaths.

• According to the same source, 400 000 youngsters are diagnosed with cancer each year.

• The eighth most common cancer in women and the 18th most prevalent cancer overall is ovarian cancer.

• The American Cancer Society predicts that 19,880 women will be newly diagnosed with ovarian cancer in the U.S. in 2022. Ovarian cancer will claim the lives of approximately 12,810 women.

Alpha emitters play an important role in killing cancerous cells using targeted therapy. Thus, the demand for alpha emitters is expected to rise at a significant rate over the coming years.

Get Customization on this Report for Specific Research Solutions –

https://www.factmr.com/connectus/sample?flag=RC&rep_id=7810

Alpha particles have drawn considerable interest from the medical research community due to their limited range and high linear energy transfer (LET), especially as a potential cancer treatment option. Ovarian cancer, lymphoma, melanoma, and pancreatic cancer are some of the cancers that are treatable with alpha emitters.

The market is primarily supported by large and sophisticated research and development initiatives being made in the cancer treatment field. This is because people are becoming more aware of the fact that certain alpha emitters can destroy cancerous cells. Accordingly, the market is being stimulated by the general population's increasing tendency for various cancers.

Key Segments in Alpha Emitters Industry Research

• By Type of Radionuclide:

  • Radium

  • Lead

  • Bismuth

  • Actinium

• By Application:

  • Bone Metastasis

  • Ovarian Cancer

  • Pancreatic Cancer

  • Melanoma

  • Lymphoma

• By Region:

  • North America

  • Latin America

  • Europe

  • East Asia

  • South Asia & Oceania

  • MEA

Get Free Access of Complete Report –

https://www.factmr.com/checkout/7810

Winning Strategy

Key suppliers of alpha emitters are continuously focusing on advancing alpha emitters by increasing research and development activities on alpha particles.

Actinium Pharmaceuticals, Inc., Alpha Tau Medical, Bayer AG, Fusion Pharma, Lantheus Medical Imaging, Inc., NTP Radiosotopes SOC Ltd., RadioMedix, Inc., Siemens Healthineers, and Triad Isotopes, Inc. are some of the major companies in the alpha emitters market.

• The novel alpha-emitter labelled peptide, AlphaMedix, for the treatment of somatostatin receptor-positive neuroendocrine tumours, was given a USD 2 million grant by the National Institutes of Health in November 2021.
  

Global Alpha Emitters Market Analysis and Forecast by Region

• North America Alpha Emitters Market Size and Forecast, 2022-2032

• Germany Alpha Emitters Market Size and Forecast, 2022-2032

• UK Alpha Emitters Market Size and Forecast, 2022-2032

• France Alpha Emitters Market Size and Forecast, 2022-2032

• Spain Alpha Emitters Market Size and Forecast, 2022-2032

• Japan Alpha Emitters Market Size and Forecast, 2022-2032

• China Alpha Emitters Market Size and Forecast, 2022-2032

• Malaysia Alpha Emitters Market Size and Forecast, 2022-2032

• Thailand Alpha Emitters Market Size and Forecast, 2022-2032

• Australia Alpha Emitters Market Size and Forecast, 2022-2032

Check out more related studies published by Fact.MR Research: 

Blood Cancer Diagnostics Market - In FY 2021, the blood cancer diagnostics market reached a valuation of US$ 15.05 Billion, and is likely to register a Y-o-Y growth rate of 5.6% in 2022, closing at US$ 15.95 Billion. Furthermore, across the 2022-2032 period of assessment, growth is expected to accelerate at a whopping 6.0% CAGR, reaching US$ 28.57 Billion.

Lung Cancer Diagnostics Market - The global lung cancer diagnostics market revenue to reach US$ 4 Bn by 2031, representing a 2x increase from 2020. Augmented development of lung cancer-specific biomarkers is propelling demand for the lung cancer diagnostics over the forecast period. Revenue from CA tests will account for US$ 1 Bn by 2031-end.

Ovarian Cancer Diagnostics Market - This global ovarian cancer diagnostics market analysis by Fact.MR predicts the industry to expand at a robust CAGR of 7% from 2021 to 2031. Fact.MR, a market research and competitive intelligence provider, has performed detailed analysis of the industry and researched all the factors that affect market growth. As per the study, the ovarian cancer diagnostics market amassed revenue worth US$ 1.3 Bn in 2020.

About Us: 

Market research and consulting agency with a difference! That’s why 80% of Fortune 1,000 companies trust us for making their most critical decisions. While our experienced consultants employ the latest technologies to extract hard-to-find insights, we believe our USP is the trust clients have on our expertise. Spanning a wide range – from automotive & industry 4.0 to healthcare & retail, our coverage is expansive, but we ensure even the most niche categories are analyzed. Our sales offices in United States and Dublin, Ireland. Headquarter based in Dubai, UAE. Reach out to us with your goals, and we’ll be an able research partner. 

Contact: 
Mahendra Singh 
US Sales Office: 
11140 Rockville Pike 
Suite 400 
Rockville, MD 20852 
Email: sales@factmr.com
Tel: +1 (628) 251-158